Evidence map›Paper›PMID 39236039›Full record

ArticlePloS one2024

Trends of primary liver cancer incidence and mortality in the United States: A population-based study over the last four decades.

Saryia Adra, Yousef Alabrach, Anas Hashem, Amir Mahmoud, Amani Khalouf, Ahmed El-Khapery, Ali Abdelhay, Mohamad Mansour, Batool Aldaher, Hiba Barqawi and 1 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. An Examination of Liver Cancer Incidence in California.Journal of registry management · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Saryia AdraCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.ORCID 0000-0002-3124-7984
Yousef AlabrachCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Anas HashemCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Amir MahmoudRochester General Hospital, Rochester, New York, United States of America.ORCID 0000-0002-0630-1117
Amani KhaloufCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Ahmed El-KhaperyCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Ali AbdelhayRochester General Hospital, Rochester, New York, United States of America.
Mohamad MansourCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Batool AldaherCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Hiba BarqawiCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.ORCID 0000-0002-8754-9172
Eman Abu-GharbiehCollege of Medicine, University of Sharjah, Sharjah, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary liver cancer is the third leading cause of cancer deaths worldwide and has one of the worst 5-year survival rates. This study examines US primary liver cancer incidence and incidence-based mortality trends over four decades. RESEARCH DESIGN AND

methodsThe SEER-9 registry was used to study primary liver cancer cases from 1978 to 2018. The incidence and mortality rates were calculated based on gender, age, race, and stage of diagnosis. Joinpoint regression software was used to calculate the annual percent change.

resultsThe overall incidence rate of primary liver cancer from 1978 to 2018 increased by 2.71%/year (p<0.001). Rates in patients <50 years old began to fall in 2002 at a rate of -3.62%/year (p<0.001). Similarly, the incidence-based mortality rates for primary liver cancer increased by 2.15%/year (p<0.001). Whereas Whites incidence-based mortality rates began to plateau in 2012 (0.18%/year; p = 0.84), Blacks rates have declined since 2010 (-2.93%/year; p = 0.03), and Asian rates have declined since 1999 (-1.30%/year; p<0.001).

conclusionWhile the overall primary liver cancer incidence and incidence-based mortality have been increasing over the last four decades, there was an observed decline in incidence and incidence-based mortality in recent years, especially among at-risk subgroups.

Indexed as

Liver NeoplasmsSEER ProgramAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedMortalitySurvival RateUnited States

Identifiers

PMID39236039
PMCPMC11376511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.